Table 5 |
|||||
|
Subgroup analysis by hormone receptor status of the benefit from taxane-containing adjuvant chemotherapy regimens |
|||||
|
HR (95% CI) for DFS |
|||||
|
|
|||||
|
Study |
Design |
Number of patients |
Stratification by hormone receptor status |
Hormone receptor positive |
Hormone receptor negative |
|
|
|||||
|
AC × 4 versus AC × 4 → P × 4 |
3,121 |
No |
0.88 (0.75–1.03)a |
0.77 (0.64–0.88) |
|
|
NSABP B-28 [15] |
AC × 4 versus AC × 4 → P × 4 |
3,060 |
Nob |
0.77 (0.65–0.92), P = 0.004 |
0.90 (0.72–1.12), P = 0.33 |
|
GEICAM 9906 [16] |
FEC × 6 versus FEC × 4 → wP × 8 |
1,248 |
No |
0.79 (0.54–1.15), P = 0.216 |
0.76 (0.51–1.12), P = 0.163 |
|
E × 4 → CMF × 4 versus E × 3 → P × 3 → CMF × 3 (q2w) |
604 |
Yes |
0.90 (0.63–1.29) |
0.69 (0.37–1.30) |
|
|
E 2197 [38] |
AC × 4 versus AT × 4 |
2,952 |
Yes |
0.99 (0.75–1.30), P = 0.96c |
1.21 (0.92–1.59), P = 0.17c |
|
USO 9735 [72] |
AC × 4 versus TC × 4 |
1,016 |
No |
0.71 (0.47–1.08) |
0.64 (0.38–1.04) |
|
BIG 02-98 [25] |
A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → T × 3 → CMF × 3 versus AT × 4 → CMF × 3 |
2,887 |
No |
D versus control: 0.86 (0.71–1.03) Sequential D versus sequential control: 0.79 (0.61–1.05) |
D versus control: 0.89 (0.69–1.15) Sequential D versus sequential control: 0.80 (0.55–1.15)d |
|
BCIRG 001 [20] |
FAC × 6 versus TAC × 6 |
1,491 |
No |
0.72 (0.56–0.92) |
0.69 (0.49–0.97) |
|
PACS 01 [21] |
FEC × 6 versus FEC × 3 → T × 3 |
1,999 |
No |
0.82 (0.63–1.07) |
0.79 (0.57–1.11) |
|
E 1199 [32] |
AC × 4 → P × 4 all q3w versus AC × 4 → P × 12w versus AC × 4 → D × 4 all q3w versus AC × 4 → D × 12w |
4,950 |
Yes |
1.31 (1.00–1.72), P = 0.05e |
1.37 (0.98–1.93), P = 0.07e |
|
|
|||||
|
Subgroup analysis by hormone receptor status of the benefit from taxane-containing adjuvant chemotherapy regimens in different reported clinical trials (Modified from Martin and coworkers [67]). aDifferences in DFS were no longer significant after adjusting for multiple comparisons. bPatients aged 45 years with hormone receptor positive tumors and all patients who were 50 years or older regardless of hormone receptor status were given tamoxifen concomitantly with chemotherapy; tamoxifen use was a stratification factor. cHR of AT versus AC and HR>1 favors the taxane arm. dPatients with hormone receptor-negative disease exhibited the largest absolute improvement in 5-year DFS when the sequential docetaxel arm (A → D → CMF) was compared with the control arms; these group had a 7% or more absolute increase in 5-year DFS compared with either control arm or the concurrent docetaxel arm. eHR>1 favors the weekly paclitaxel arm. A, doxorubicin; C, cyclophosphamide; DFS, disease-free survival; E, epirubicin; F, 5-fluorouracil; T, docetaxel; w, week. |
|||||
|
López-Tarruella and Martín Breast Cancer Research 2009 11:204 doi:10.1186/bcr2226 |
|||||